Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469386 | 0.72 | ALDH1A1 (0.72) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10830069 | 0.70 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL1996863 | 0.68 | — | — | |
| SCHEMBL30066038 | 0.68 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBSMN1; SMN2HPGD | |
| SCHEMBL12403890 | 0.68 | ALDH1A1 (0.40) | ALDH1A1SCN8ASCN10APOLBSMN1; SMN2 | |
| SCHEMBL12473388 | 0.68 | MAPT (0.41) | ALDH1A1LMNASCN8ASCN10APOLB | |
| SCHEMBL28223523 | 0.67 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL13135971 | 0.67 | SMN1; SMN2 (0.52) | ALDH1A1SCN8ASCN10APOLBSMN1; SMN2 | |
| SCHEMBL18893523 | 0.65 | AR (0.43) | ALDH1A1LMNASCN8ASCN10ASMN1; SMN2 | |
| SCHEMBL11119158 | 0.65 | LMNA (0.57) | ALDH1A1LMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795116-B | Tosylate of MEK kinase inhibitor, crystal form and preparation method thereof | JIANGSU HENGRUI MEDICINE CO.,LTD. (CN) | 2019-11-01 | — | — | CN | claimed |
| CN-109790146-A | Medical compounds | 阿尔麦克探索有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109641874-A | C for target protein degradation3The glutarimide degron body of carbon connection | C4医药公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562107-A | Heterocyclic degrading ligand for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109195965-A | The inhibitor that WDR5 protein-protein combines | 普罗佩纶治疗公司 | 2019-01-11 | — | — | CN | disclosed |